Global Radiopharmaceuticals in Nuclear Medicine Market Size was estimated at USD 4809.89 million in 2022 and is projected to reach USD 6790.59 million by 2028, exhibiting a CAGR of 5.05% during the forecast period.
Global Radiopharmaceuticals in Nuclear Medicine Market Overview:
Global Radiopharmaceuticals in Nuclear Medicine Market Report 2022 comes with the extensive industry analysis with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Radiopharmaceuticals in Nuclear Medicine involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Radiopharmaceuticals in Nuclear Medicine Market
The Radiopharmaceuticals in Nuclear Medicine Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Radiopharmaceuticals in Nuclear Medicine Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Radiopharmaceuticals in Nuclear Medicine Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Radiopharmaceuticals in Nuclear Medicine Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Radiopharmaceuticals in Nuclear Medicine market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Radiopharmaceuticals in Nuclear Medicine Market Segmentation
Global Radiopharmaceuticals in Nuclear Medicine Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Radiopharmaceuticals in Nuclear Medicine market has been segmented into:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
By Application, Radiopharmaceuticals in Nuclear Medicine market has been segmented into:
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Radiopharmaceuticals in Nuclear Medicine market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Radiopharmaceuticals in Nuclear Medicine market.
Top Key Players Covered in Radiopharmaceuticals in Nuclear Medicine market are:
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories
Inc.
Cardinal Health
Inc.
Covidien
Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec
Inc. (Sigma-Aldrich)
Lantheus Medical Imaging
Inc.
Nordion
Inc.
Ntp Radioisotopes (Pty)
Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries
Ltd.
Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co.
Ltd.
Institute Of Radioelement (IRE)
Objective to buy this Report:
1. Radiopharmaceuticals in Nuclear Medicine analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Radiopharmaceuticals in Nuclear Medicine market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Radiopharmaceuticals in Nuclear Medicine Market by Type
5.1 Radiopharmaceuticals in Nuclear Medicine Market Overview Snapshot and Growth Engine
5.2 Radiopharmaceuticals in Nuclear Medicine Market Overview
5.3 Diagnostic Radiopharmaceuticals
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Diagnostic Radiopharmaceuticals: Geographic Segmentation
5.4 Therapy Radiopharmaceuticals
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Therapy Radiopharmaceuticals: Geographic Segmentation
5.5 Enriched Stable Isotopes
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Enriched Stable Isotopes: Geographic Segmentation
Chapter 6: Radiopharmaceuticals in Nuclear Medicine Market by Application
6.1 Radiopharmaceuticals in Nuclear Medicine Market Overview Snapshot and Growth Engine
6.2 Radiopharmaceuticals in Nuclear Medicine Market Overview
6.3 Diagnostic Application
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Diagnostic Application: Geographic Segmentation
6.4 Therapeutic Application
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Therapeutic Application: Geographic Segmentation
6.5 Research
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Research: Geographic Segmentation
6.6 Pharmaceutical
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2028F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Pharmaceutical: Geographic Segmentation
6.7 Other
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2016-2028F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Radiopharmaceuticals in Nuclear Medicine Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Radiopharmaceuticals in Nuclear Medicine Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Radiopharmaceuticals in Nuclear Medicine Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 BRACCO IMAGING S.P.A.
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 CAMBRIDGE ISOTOPE LABORATORIES
7.4 INC.
7.5 CARDINAL HEALTH
7.6 INC.
7.7 COVIDIEN
7.8 PLC
7.9 ECZACIBASI-MONROL
7.10 FUJIFILM HOLDINGS CORPORATION
7.11 GE HEALTHCARE (SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
7.12 IBA GROUP
7.13 ISOTEC
7.14 INC. (SIGMA-ALDRICH)
7.15 LANTHEUS MEDICAL IMAGING
7.16 INC.
7.17 NORDION
7.18 INC.
7.19 NTP RADIOISOTOPES (PTY)
7.20 LTD.
7.21 SIEMENS HEALTHCARE (SUBSIDIARY OF SIEMENS AG)
7.22 TAIYO NIPPON SANSO CORPORATION
7.23 URENCO LIMITED
7.24 ROTEM INDUSTRIES
7.25 LTD.
7.26 INC.
7.27 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO)
7.28 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT)
7.29 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE
7.30 INSTITUTE OF ISOTOPES CO.
7.31 LTD.
7.32 INSTITUTE OF RADIOELEMENT (IRE)
Chapter 8: Global Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Diagnostic Radiopharmaceuticals
8.2.2 Therapy Radiopharmaceuticals
8.2.3 Enriched Stable Isotopes
8.3 Historic and Forecasted Market Size By Application
8.3.1 Diagnostic Application
8.3.2 Therapeutic Application
8.3.3 Research
8.3.4 Pharmaceutical
8.3.5 Other
Chapter 9: North America Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Diagnostic Radiopharmaceuticals
9.4.2 Therapy Radiopharmaceuticals
9.4.3 Enriched Stable Isotopes
9.5 Historic and Forecasted Market Size By Application
9.5.1 Diagnostic Application
9.5.2 Therapeutic Application
9.5.3 Research
9.5.4 Pharmaceutical
9.5.5 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Diagnostic Radiopharmaceuticals
10.4.2 Therapy Radiopharmaceuticals
10.4.3 Enriched Stable Isotopes
10.5 Historic and Forecasted Market Size By Application
10.5.1 Diagnostic Application
10.5.2 Therapeutic Application
10.5.3 Research
10.5.4 Pharmaceutical
10.5.5 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
Chapter 11: Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Diagnostic Radiopharmaceuticals
11.4.2 Therapy Radiopharmaceuticals
11.4.3 Enriched Stable Isotopes
11.5 Historic and Forecasted Market Size By Application
11.5.1 Diagnostic Application
11.5.2 Therapeutic Application
11.5.3 Research
11.5.4 Pharmaceutical
11.5.5 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
Chapter 12: Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Diagnostic Radiopharmaceuticals
12.4.2 Therapy Radiopharmaceuticals
12.4.3 Enriched Stable Isotopes
12.5 Historic and Forecasted Market Size By Application
12.5.1 Diagnostic Application
12.5.2 Therapeutic Application
12.5.3 Research
12.5.4 Pharmaceutical
12.5.5 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
Chapter 13: South America Radiopharmaceuticals in Nuclear Medicine Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Diagnostic Radiopharmaceuticals
13.4.2 Therapy Radiopharmaceuticals
13.4.3 Enriched Stable Isotopes
13.5 Historic and Forecasted Market Size By Application
13.5.1 Diagnostic Application
13.5.2 Therapeutic Application
13.5.3 Research
13.5.4 Pharmaceutical
13.5.5 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
Chapter 14 Investment Analysis
Chapter 15 Analyst Viewpoint and Conclusion
Publisher: Introspective Market Research
Related Reports
- Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)
- Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)
- Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support
Frequently Asked Questions (FAQ)
Global Radiopharmaceuticals in Nuclear Medicine Market Size was estimated at USD 4809.89 million in 2022 and is projected to reach USD 6790.59 million by 2028.
Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group, Isotec, Inc. (Sigma-Aldrich), Lantheus Medical Imaging, Inc., Nordion, Inc., Ntp Radioisotopes (Pty), Ltd., Siemens Healthcare (Subsidiary Of Siemens AG), Taiyo Nippon Sanso Corporation, Urenco Limited, Rotem Industries, Ltd., Inc., Australian Nuclear Association And Technology Organization (ANSTO), Board of Radiation And Isotope Technology (BRIT), Institute of Atomic Energy Polatom Radioisotope Centre, Institute of Isotopes Co., Ltd., Institute Of Radioelement (IRE)
North America,Europe,Asia-Pacific,South America,Middle East & Africa